Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid ...

Résumé détaillé

Capitalize on personalized medicine, advanced genetic testing and cancer diagnostics with tariff-aware sourcing, regional analysis and competitive insights.Dublin, Nov. 11, 2026…

Capitalize on personalized medicine, advanced genetic testing and cancer diagnostics with tariff-aware sourcing, regional analysis and competitive insights.

Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Molecular Cytogenetics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global molecular cytogenetics market was valued at US$2.1 billion in 2024 and is projected to reach US$3.5 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2030. The comprehensive market report examines industry trends, growth drivers, competitive developments, regional opportunities, and forecasts to support informed strategic planning. It also assesses recent global tariff developments and their impact on molecular cytogenetics supply chains, sourcing strategies, costs, and market expansion.

Technologies including fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), array CGH, immunohistochemistry, and karyotyping support the detection and analysis of chromosomal abnormalities and genetic variations. These capabilities are increasingly important in genetic disorder diagnosis, oncology, prenatal screening, clinical research, and personalized medicine.

Technological advances are strengthening the accuracy, speed, and clinical utility of molecular cytogenetics. High-throughput sequencing, next-generation sequencing, microarrays, automation, and bioinformatics platforms are improving the identification and interpretation of complex genomic alterations. These developments are also extending molecular cytogenetics applications into population genetics, evolutionary biology, translational research, and precision oncology.

Market growth is being supported by the rising prevalence of cancer and genetic disorders, increasing adoption of personalized medicine, and continued investment in genomics research.

The consumables segment is forecast to reach US$2 billion by 2030, growing at a CAGR of 8.9%.

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.